Shares of Silo Pharma, Inc. (SILO) are surging more than 50% Friday morning after the company reported positive data for its drug candidate SPU-21 for the treatment of Arthritis.
The company today announced positive interim data from its dose optimization study of SPU-21 joint homing peptides for subcutaneous administration of anti-arthritic agents.
Silo Pharma said it is pursuing a development plan utilizing its liposomal joint homing peptides as a potential therapy for rheumatoid arthritis (RA).
SILO, currently at $5.21, has traded in the range of $0.17-$12.45 in the last 1 year.
Source: Read Full Article
Lates News:
-
Denali Therapeutics Down After Proposing To Sell $250 Million Of Shares
-
Bitcoin Heads Towards $30,000 As It Hits New Peak Despite Ongoing Market Woes
-
How Far Away Is The $50,000 Price From the Bitcoin Market? Here’s What to Watch Out For
-
Cryptos Gain As Wall Street Rebounds
-
Riding the Crypto Wave: Novogrtz’s Investment Strategy in Uncertain Economic Times